Autopsy report · NCT01125501

Protandim and the Metabolic Syndrome

“funding not available”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

SomaLogic, Inc.

Sponsor type

Industry

Conditions

Metabolic Syndrome

Interventions

Protandim

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
  “Funding was not available” (95% match in meaning)
• Optical Coherence Tomography in Staging Patients With Upper Tract Urothelial Cancer
  “Funding unavailable” (95% match in meaning)
• Evaluation and Adverse Event Surveillance for Initial Implementation of ShangRing Circumcision in Mozambique
  “Funding no longer available” (92% match in meaning)
• Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
  “Funding has become unavailable” (92% match in meaning)
• A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC).
  “Unavailable funding” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.